Targeting the mTOR Pathway: A New Horizon in Oral Cancer Treatment

• This editorial examines the critical role of the mTOR pathway in oral cancer progression and resistance to conventional therapies. • Detailed exploration of genetic and epigenetic alterations leading to hyperactivation of the mTOR pathway in oral cancer. • Discussion on the efficacy of mTOR inhibitors, challenges faced, and the development of second-generation inhibitors targeting both mTORC1 and mTORC2. • Insight into the promising results of combining mTOR inhibitors with other targeted agents and immune checkpoint inhibitors to enhance therapeutic efficacy. • Focusing research on dual mTORC1/mTORC2 inhibitors and biomarker identification to enhance personalized treatment for oral cancer patients.